Effects of CYP3A4 inhibition and induction on the pharmacokinetics ...

Tolvaptan is a sensitive CYP3A4 substrate with no inhibitory activity. Due to the saturable nature of tolvaptan's effect on urine excretion rate, ...

To determine the effect of a CYP3A4 inhibitor (ketoconazole) and a CYP3A4 inducer (rifampicin) on tolvaptan pharmacokinetics (PK) and pharmacodynamics (PD), ...

Effect of CYP3A4 Inhibitors and Inducers on Pharmacokinetics and ...

Ketoconazole, delavirdine, and rifampicin were selected as a CYP3A4 competitive inhibitor, a time-dependent inhibitor, and an inducer, ...

Effect of CYP3A4 induction and inhibition on the pharmacokinetics ...

Clinical studies were performed to evaluate the effects of a strong CYP3A4 inducer, rifampin, and a strong CYP3A4 inhibitor, itraconazole, on the ...

Full article: Effects of CYP3A4 Inhibition/Induction and OATP ...

Itraconazole, a strong inhibitor of CYP3A4, was selected to assess the effect of CYP3A4 inhibitors on the pharmacokinetics (PK) of atogepant [Citation21].

Effects of CYP3A4 and P-glycoprotein inhibition or induction on the ...

The PK of ubrogepant were significantly affected by the concomitant use of CYP3A4 moderate-strong inhibitors and strong inducers.

The effect of CYP3A4 inhibition or induction on the ... - DrugBank

The effects of inhibition or induction of CYP3A4 on single oral dose ruxolitinib pharmacokinetics (PK) and pharmacodynamics (PD) were evaluated in healthy ...

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 ...

No reversible or time-dependent inhibition of human CYPs at concentrations up to 30 µM in vitro was observed for FMGX. Reversible inhibition ...

Drug Metabolism - The Importance of Cytochrome P450 3A4

The magnitude of CYP3A4 induction can be substantial. Induction becomes apparent more slowly than inhibition and it takes more time for the ...

Effects of CYP3A4 inhibition and induction on the pharmacokinetics ...

To determine the effect of a CYP3A4 inhibitor. (ketoconazole) and a CYP3A4 inducer (rifampicin) on tolvaptan pharmacokinetics (PK) and ...

Influence of CYP3A4 Induction/Inhibition on the Pharmacokinetics of ...

In vitro and in vivo studies indicate that vilazodone does not inhibit or induce cytochrome P-450 (CYP) isozymes except for potential inhibition ...

Inhibition and induction of CYP enzymes in humans: an update

The inhibition and induction of CYPs are major mechanisms causing pharmacokinetic drug–drug interactions. This review presents a comprehensive ...

Quantitative prediction of CYP3A induction-mediated drug-drug ...

Its inhibition and induction can greatly affect the maximum plasma concentrations (Cmax) and area under the curve (AUC) of CYP3A substrate drugs by changing ...

Perspectives from the Innovation and Quality Consortium Induction ...

With selective CYP3A substrates, the net effect was often inhibition, whereas less selective substrates could discern induction through ...

Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and ...

Rifampicin induces many CYPs but exerts its most potent induction on CYP3A4. Since selumetinib will be given to patients who are potentially ...

A Review of CYP3A Drug-Drug Interaction Studies - Frontiers

The effect of moderate or weak inhibitors or inducers can be examined using physiologically based pharmacokinetic simulations, but data from ...

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 ...

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in ...

The Effect of Cytochrome P450 Metabolism on Drug Response ...

Although this class has more than 50 enzymes, six of them metabolize 90 percent of drugs, with the two most significant enzymes being CYP3A4 and ...

Effects of CYP3A4 inhibition and induction on the pharmacokinetics ...

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. · 63 ...

(PDF) Effect of CYP3A4 Inhibitors and Inducers on ... - ResearchGate

Ketoconazole, delavirdine, and rifampicin were selected as a CYP3A4 competitive inhibitor, a time-dependent inhibitor, and an inducer, ...